# Right ventricle remodeling in pulmonary hypertension

> **NIH NIH R01** · OHIO STATE UNIVERSITY · 2024 · $48,386

## Abstract

PROJECT SUMMARY/ABSTRACT
Failure of the right ventricle (RV) is a main component of the morbidity and mortality of pulmonary hypertension
(PH). There exists no specific treatment for RV dysfunction and failure and the only cure for many patients
(especially in the case of pulmonary arterial hypertension) remains transplantation. This is partially due to the
critical lack of understanding of RV biology; therapeutic strategies that are beneficial for LV failure have worse
outcomes when applied to those with RV failure. What has been observed in RV dysfunction in human subjects
and animal models is exaggerated fibrosis and divergent contractile and hypertrophic responses to several drugs
when compared to LV dysfunction. Thus, the RV may contain distinct pathobiology compared to the LV that has
high significance for treatment of PH. Cardiac myocytes may have distinct cell signaling properties in the RV,
though there is a lot unknown about these differences. Previous work has shown that RV cardiac myocytes,
compared to those from the LV, have increased K+ current, shorter action potential duration, reduced sarcomere
shortening, and reduced peak intracellular Ca2+ when compared to LV cardiac myocytes. These differences
demonstrate that RV cardiac myocytes may have molecular differences at a functional level. This diversity
supplement will determine how contractility, calcium handling, and size of the cardiac myocyte change during
RV remodeling in PH, and determine and test novel drug targets that alter RV contractility. These data may
uncover novel understanding of RV cardiac myocyte biology and lead to further therapeutic strategies for right
heart failure. This supplement will address this concern with two Specific Aims: (1) Determine the mechanism of
cardiac myocyte adaptation to RV pressure overload. and (2) Interrogate GPCR targets in the RV as potential
therapeutic targets.

## Key facts

- **NIH application ID:** 11097888
- **Project number:** 3R01HL167963-01A1S1
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Matthew William Gorr
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $48,386
- **Award type:** 3
- **Project period:** 2024-01-01 → 2028-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11097888

## Citation

> US National Institutes of Health, RePORTER application 11097888, Right ventricle remodeling in pulmonary hypertension (3R01HL167963-01A1S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11097888. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*